LePage Daniel F.
Known title: DirectorCIK: 0001811455
Associated companies
this person other insiders at DHC
Transaction History
| DHC | ▲ Buy | Grant | 20,000 | — | 6/5/2023 | View on chart |
| DHC | ▲ Buy | Grant | 20,000 | — | 6/2/2022 | View on chart |
| DHC | ▲ Buy | Grant | 20,000 | — | 6/5/2023 | View on chart |
| DHC | ▲ Buy | Grant | 20,000 | — | 6/2/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
DHC REITs Show Signs of Stabilization Amid Market Recovery
A recent report notes that Real Estate Investment Trusts have halted their recent decline, suggesting a potential shift in sentiment for the sector. DHC, as a healthcare-focused REIT, is part of this broader group. The stock currently trades near its support level, with a dividend yield of 1.94% and an average analyst target of $10.15.
DHC REITs Show Signs of Stabilization Amid Market Recovery. A recent report notes that Real Estate Investment Trusts have halted their recent decline, suggesting a potential shift in sentiment for the sector. DHC, as a healthcare-focused REIT, is part of this broader group. The stock currently trades near its support level, with a dividend yield of 1.94% and an average analyst target of $10.15.